These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 33340905)
1. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region. Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905 [TBL] [Abstract][Full Text] [Related]
2. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial. Karch A; Koch A; Grünwald V Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325 [TBL] [Abstract][Full Text] [Related]
3. Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. Subbiah V; Meyer C; Zinner R; Meric-Bernstam F; Zahurak ML; O'Connor A; Roszik J; Shaw K; Ludwig JA; Kurzrock R; Azad NA Clin Cancer Res; 2017 Aug; 23(15):4027-4034. PubMed ID: 28377484 [No Abstract] [Full Text] [Related]
4. Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study. Koca S; Beşiroğlu M; Özçelik M; Karaca M; Bilici M; Hacıoğlu B; Doğu GG; Kaplan NB; Oruç Z; Aydın D; Dane F J Oncol Pharm Pract; 2021 Apr; 27(3):541-546. PubMed ID: 32419618 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. Cesne AL; Bauer S; Demetri GD; Han G; Dezzani L; Ahmad Q; Blay JY; Judson I; Schöffski P; Aglietta M; Hohenberger P; Gelderblom H BMC Cancer; 2019 Aug; 19(1):794. PubMed ID: 31409302 [TBL] [Abstract][Full Text] [Related]
6. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study. Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656 [TBL] [Abstract][Full Text] [Related]
7. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Somaiah N; Van Tine BA; Wahlquist AE; Milhem MM; Hill EG; Garrett-Mayer E; Armeson KE; Schuetze SM; Meyer CF; Reuben DY; Elias AD; Read WL; Chawla SP; Kraft AS Cancer; 2021 Mar; 127(6):894-904. PubMed ID: 33231866 [TBL] [Abstract][Full Text] [Related]
8. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. Schulte B; Mohindra N; Milhem M; Attia S; Robinson S; Monga V; Hirbe AC; Oppelt P; Charlson J; Helenowski I; Abbinanti S; Cehic R; Okuno S; Van Tine BA; Agulnik M Br J Cancer; 2021 Aug; 125(4):528-533. PubMed ID: 34050255 [TBL] [Abstract][Full Text] [Related]
10. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers. Van Tine BA; Trent JC Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922 [TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors. Nishida Y; Urakawa H; Nakayama R; Kobayashi E; Ozaki T; Ae K; Matsumoto Y; Tsuchiya H; Goto T; Hiraga H; Naka N; Takahashi S; Ando Y; Ando M; Kuwatsuka Y; Hamada S; Ueda T; Kawai A Int J Cancer; 2021 Jan; 148(1):140-149. PubMed ID: 32638374 [TBL] [Abstract][Full Text] [Related]
12. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174 [TBL] [Abstract][Full Text] [Related]
13. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation. Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944 [TBL] [Abstract][Full Text] [Related]
14. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823 [TBL] [Abstract][Full Text] [Related]
15. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D; Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858 [TBL] [Abstract][Full Text] [Related]
16. Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world. Bajpai J; Mullapally SK; Kapoor A; Ghosh J; Rekhi B Indian J Cancer; 2021; 58(3):365-370. PubMed ID: 33753596 [TBL] [Abstract][Full Text] [Related]
17. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011 [TBL] [Abstract][Full Text] [Related]
18. Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population. Huang PW; Chou WC; Shen WC; Hung CY; Huang KG; Su YL; Lu CH; Liu CT; Chang YS; Liau CT Asia Pac J Clin Oncol; 2018 Aug; 14(4):353-360. PubMed ID: 29900662 [TBL] [Abstract][Full Text] [Related]
19. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. Grünwald V; Karch A; Schuler M; Schöffski P; Kopp HG; Bauer S; Kasper B; Lindner LH; Chemnitz JM; Crysandt M; Stein A; Steffen B; Richter S; Egerer G; Ivanyi P; Zimmermann S; Liu X; Kunitz A J Clin Oncol; 2020 Oct; 38(30):3555-3564. PubMed ID: 32840417 [TBL] [Abstract][Full Text] [Related]
20. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy. Hirbe AC; Eulo V; Moon CI; Luo J; Myles S; Seetharam M; Toeniskoetter J; Kershner T; Haarberg S; Agulnik M; Monga V; Milhem M; Parkes A; Robinson S; Okuno S; Attia S; Van Tine BA Eur J Cancer; 2020 Sep; 137():1-9. PubMed ID: 32712457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]